focus -WSS

focus

author：comprehensive 2025-10-01 22:58:07 - browse：6

U.S. President Joe Biden stands with his fingers locked next to an US flag — politics coverage from STAT — President Biden's White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs.

WASHINGTON — The White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs, its latest effort to draw attention to the program in an election year.

The news is not controversial: The pharmaceutical companies that make the first ten drugs up for negotiation all submitted counteroffers. It’s an incremental step in the new program, which was created in 2022.

Earlier this year, Medicare sent its initial price offers to the companies. Neither the Biden administration nor the drug manufacturers have volunteered any information about the White House’s initial price offers or the counteroffers. The process is scheduled to end by Aug. 1.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Methadone treatment changes are coming. Do they go far enough?

WSS

Virtual Event: March of the Biosimilars

Brain MRIs reveal impact of 'toxic stress' on Black children

AI for drug discovery: Experts on separating hype from reality

Deliver public health messages at the right time

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

AstraZeneca to buy developer of next

explore

focus

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

AI for drug discovery: Experts on separating hype from reality

Medicare proposal to cover medical devices draws a mixed reaction

5 to watch: Tech startups trying to solve health care's staffing crisis

Bright Health sells Medicare Advantage business to Molina

Future doctors should be trained to promote social change

Sports medicine is finally prioritizing gender equality

AstraZeneca to buy developer of next

How to save PrEP access — and even expand it

AI for drug discovery: Experts on separating hype from reality

Wikipedia

Crowdfunding for medical bills sidesteps core problem, author says

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Novel spinal cord stimulator treats paralysis without surgery

PBM executives asked to testify by House panel

Orchard's therapy for neuron disease in children wins FDA approval

The effects of a landmark ruling on DNA ownership are becoming clearer

leisure time

entertainment

focus

hotspot